A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

After Eli Lilly and Biogen’s setbacks in developing O-GlaNAcase (OGA) inhibitors for Alzheimer’s disease, Asceneuron has now ...

Marvell beats expectations with its latest quarterly results and outlook, but that's not enough to lift the stock Better-than-expected results and guidance from Marvell Technology Inc. weren't enough ...

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share, bringing the deal in at about $935 million. Jazz expands its cancer pipeline with the new acquisition’s lead candidate, dordaviprone ...